These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 28515029

  • 1. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P.
    J Clin Res Pediatr Endocrinol; 2017 Sep 01; 9(3):288-292. PubMed ID: 28515029
    [Abstract] [Full Text] [Related]

  • 2. [Current options of treatment of hyponatremia].
    Tesař V.
    Vnitr Lek; 2016 Sep 01; 62 Suppl 6():97-101. PubMed ID: 28124939
    [Abstract] [Full Text] [Related]

  • 3. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W, Głuszek J.
    Pol Arch Med Wewn; 2007 Aug 01; 117(8):356-62. PubMed ID: 18018383
    [Abstract] [Full Text] [Related]

  • 4. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A.
    J Clin Endocrinol Metab; 2013 Apr 01; 98(4):1321-32. PubMed ID: 23401044
    [Abstract] [Full Text] [Related]

  • 5. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 01; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 6. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 01; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 7. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F.
    Orv Hetil; 2008 Jul 20; 149(29):1347-54. PubMed ID: 18617466
    [Abstract] [Full Text] [Related]

  • 8. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S.
    Hosp Pract (1995); 2017 Aug 20; 45(3):111-117. PubMed ID: 28449624
    [Abstract] [Full Text] [Related]

  • 9. [From hyponatremia to tolvaptan].
    Cernaro V, Santoro D, Lacquaniti A, Montalto G, Buemi M.
    G Ital Nefrol; 2014 Aug 20; 31(1):. PubMed ID: 24671837
    [Abstract] [Full Text] [Related]

  • 10. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
    Gross PA, Wagner A, Decaux G.
    Kidney Int; 2011 Sep 20; 80(6):594-600. PubMed ID: 21451459
    [Abstract] [Full Text] [Related]

  • 11. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L, Schmidt PH, Gheorghiade M.
    Expert Rev Cardiovasc Ther; 2011 Dec 20; 9(12):1505-13. PubMed ID: 22103869
    [Abstract] [Full Text] [Related]

  • 12. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R.
    Support Care Cancer; 2016 Jan 20; 24(1):499-507. PubMed ID: 26431960
    [Abstract] [Full Text] [Related]

  • 13. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 20; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 14. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
    Yamashita T, Yoshida M, Yamada H, Asano T, Aoki A, Ikoma A, Kusaka I, Kakei M, Ishikawa SE.
    Intern Med; 2014 Apr 20; 53(8):845-9. PubMed ID: 24739604
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 20; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 16. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C, Balbiano R, Caramello P, Roccatello D.
    G Ital Nefrol; 2013 Dec 20; 30(6):. PubMed ID: 24402662
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P, Muduganti SR, Mujibur R, Murali N.
    WMJ; 2015 Apr 20; 114(2):66-8. PubMed ID: 26756059
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C, Robinson P, O'Reilly K, Lundberg J, Gisby M, Ländin M, Skov J, Trueman D.
    BMC Endocr Disord; 2016 May 16; 16(1):22. PubMed ID: 27184496
    [Abstract] [Full Text] [Related]

  • 19. Treatment of hyponatremia induced by the syndrome of Inappropriate antidiuretic hormone secretion: a multidisciplinary spanish algorithm.
    Runkle I, Villabona C, Navarro A, Pose A, Formiga F, Tejedor A, Poch E.
    Nefrologia; 2014 May 16; 34(4):439-50. PubMed ID: 25036057
    [Abstract] [Full Text] [Related]

  • 20. [Vasopressin receptor antagonists: the vaptans].
    Villabona C.
    Endocrinol Nutr; 2010 May 16; 57 Suppl 2():41-52. PubMed ID: 21130961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.